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Differences between anti-myeloperoxidase. and anti-proteinase 3-asso-
ciated renal disease. We performed a retrospective study of the clinical
features, the pattern of the pre-treatment renal function loss, the renal
morphology and the outcome in 92 patients with anti-neutrophil cytoplas-
mic autoantibodies directed against proteinase 3 (aPR3; N = 46) or
myeloperoxidase (aMPO; N = 46). Patients with aMPO had a higher
median age than patients with aPR3 (63 and 56 years; P < 0.05). The
mean (±sn) number of affected organs in the aPR3 group exceeded that
of the aMPO group (3.9 1.4 and 2.2 1.1; P < 0.01). The prevalence
of renal involvement did not differ between patients with aPR3 and aMPO
(83% and 67%, respectively; NS). Pre-treatment renal function deterio-
rated significantly faster in aPR3- than in aMPO-associated renal disease.
The kidney biopsies from patients with aPR3 showed a higher activity
index (10.2 3.8 and 7.3 3.2; P < 0.03) and a lower chronicity index
(4,5 2.6 and 7.0 3.1;P < 0.02) than biopsies from patients with aMPO.
The kidney survival at two years was 73% in patients with aPR3- and 61%
in patients with aMPO-associated renal disease (NS). We conclude that
renal function generally deteriorates faster in aPR3- than in aMPO-
associated renal disease. This goes together with more active renal lesions
in patients with aPR3 and more chronic renal lesions in patients with
aMPO. Despite these differences, there is no difference in outcomes
between both antibody groups.
Anti-neutrophil cytoplasmic autoantibodies (ANCA) are useful
serological markers for vasculitis [1]. Two major patterns of
ANCA have been recognized by indirect immunofluorescence
microscopy (hF): one with cytoplasmic (c-ANCA) and one with
perinuclear staining (p-ANCA) [2, 3]. c-ANCA are nearly always
aimed at proteinase-3 (PR3) [4, 5]. The major p-ANCA target is
myeloperoxidase (MPO), but antibodies against other neutrophil
antigens (for example, elastase, lactoferrin, eosinophilic peroxi-
dase) and non-organ specific antinuclear antibodies can produce a
similar pattern [2, 4, 6—11].
Autoantibodies directed against PR3 (aPR3) and MPO
(aMPO) are both associated with pauci-immune necrotizing and
crescentic glomerulonephritis [12, 13]. However, important differ-
ences in associated diseases are recognized. aPR3 are predomi-
nantly found in patients with Wegener's granulomatosis, micro-
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scopic polyangiitis and the so-called pulmonary-renal-sinus
syndrome [11, 13]. aMPO have been noted in a high proportion of
patients with necrotizing and crescentic glomerulonephritis, either
as the sole disease manifestation or as a part of a systemic
vasculitis [10—12]. Upon histological examination, granuloma
formation is almost exclusively observed in patients with aPR3 [9,
14].
Although distinct differences do apparently exist, there are very
few studies that have compared the course of the pre-treatment
renal function loss, the renal pathology [14], and the outcome [1,
15] between patients with aPR3- and aMPO-associated renal
disease. In a previous study we observed a protracted course of
renal function loss in some patients with aMPO-associated cres-
centic glomerulonephritis, whereas such a clinical course was not
observed in patients with aPR3 [16]. The objective of this study
was, therefore, to determine whether or not there are differences
in the clinical presentation, the renal morphology and the out-
come between patients with aPR3 and aMPO. In addition, we
studied whether certain clinical and morphological characteristics
are predictive of the outcome.
Methods
Patients
The study was conducted in three hospitals in the Netherlands
(Catharina Hospital, Eindhoven; Free University Hospital, Am-
sterdam; St. Joseph Hospital, Veldhoven, The Netherlands). They
are general teaching hospitals and none of them is a specific
referral center for vasculitic diseases. They have been testing for
ANCA by hF since January, 1985 in patients suspected of having
vasculitis and/or glomerulonephritis. Since January, 1988, ANCA-
hF positive sera have been sent to the Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service (Amsterdam)
for antigen determination by catching ELISA [4]. All samples
were assayed for the presence of autoantibodies against protein-
ase 3, myeloperoxidase and elastase. By means of the data files
from this laboratory, all patients from the above hospitals who had
tested positive for aPR3 or aMPO between January, 1988 and
January, 1993 were identified. In addition, we included six patients
who had tested ANCA-positive by hF between January, 1985 and
January, 1988 and whose sera were still available for antigen
determination, revealing aPR3 or aMPO. In order to rule out
'long survival bias,' we excluded patients who had already been
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diagnosed with vasculitis and/or glomerulonephritis before the
introduction of the ANCA-IIF test (Janualy 1985) or suffered
from exacerbations of a previously known vasculitic disease.
The charts of all patients were reviewed by two of the authors
(CFMF, SJH).
Parameters and definitions
Renal involvement was defined as microscopic hematuria (>5
red blood cells per high power field) and/or proteinuria (by biuret
method or albustix testing; lower detection limits 0.2 g/liter and
0.3 glliter, respectively) occurring on two separate occasions.
Extra-renal involvement was categorized as described previously
[17]. In short, the following criteria were used for organ involve-
ment: upper respiratory tract—nasal mucosal ulceration, serous
otitis media, sinusitis, tracheal stenosis; lower respiratory tract—
pulmonary infiltrates, coin lesions, asthma, alveolar hemorrhage;
skin—palpable purpura, ulcera or nodules; nervous system—
mononeuritis multiplex, peripheral neuropathy; musculoskeletal
tract—arthralgias, arthritis, polymyalgia rheumatica; eyes—(epi-)
scleritis, keratitis, uveitis, retinal vasculitis; heart—pericarditis,
myocardial infarction, cardiomyopathy; gastrointestinal tract—
bowel perforation, aneurysms by abdominal angiography. Any
manifestation was considered only in the absence of other condi-
tions related to that manifestation such as drugs, infections or
atherosclerotic disease. For each patient the total number of
affected organs was determined. The upper respiratory tract,
lower respiratory tract, kidneys, eyes, skin, nervous system, heart,
musculoskeletal system and gastrointestinal tract were regarded
as so many separate organ systems.
For the sake of clinical comparison, the patients with renal
involvement were further characterized as follows: (1.) renal-
limited disease; patients with arthralgia as the only extra-renal
manifestation were also included in this group; (2.) renal disease
and nonpulmonary extra-renal disease; (3.) concomitant pulmo-
nary and renal disease, with or without upper respiratory tract
involvement (pulmonary-renal disease).
The baseline serum creatinine was defined as the last serum
creatinine value measured before immunosuppressive treatment
(cyclophosphamide and/or steroids) or renal replacement therapy
was begun. If no immunosuppressive treatment was given, the
serum creatinine level at the time of diagnosis was used as the
baseline value.
The pre-treatment rate of renal function loss, that is, the loss of
renal function before any immunosuppressive treatment or renal
replacement therapy was instituted, was assessed as follows: for
each patient the time interval during which serum creatinine
doubled was determined from all available pre-treatment serum
creatinine values. A doubling of serum creatinine within the two
weeks before the start of treatment was named 'renal crisis.' Next,
for each patient the rate of renal function loss was determined by
the slope of the linear regression line obtained by plotting the
reciprocal of the pre-treatment serum creatinine values against
time. For patients to be included in this analysis, a minimum of
two serum creatinine values, spaced seven days apart, had to be
available before any immunosuppressive therapy and/or renal
replacement therapy was instituted.
Death was considered to be therapy-related if it was caused by
an opportunistic infection or bleeding, secondary to drug-induced
leukocytopenia or thrombocytopenia.
Histological studies
All kidney biopsies were evaluated by the same pathologist
(ROBG), who was unaware of the ANCA specificity. Each biopsy
was scored according to an activity and chronicity index as
reported previously [16]. In short, all histologic lesions were
semiquantitatively graded on a scale of 0,1,2,3 (absent, mild,
moderate and severe, respectively). Necrosis, cellular crescents
and fibrous crescents were weighted by a factor of two. The
maximal possible scores for the activity index and the chronicity
index were 24 and 18, respectively.
Statistical analysis
The differences in the prevalence of organ involvement and in
the treatment modalities between groups were tested by means of
the chi-square test. Differences in patient age, the number of
affected organs, the slope of the regression lines, the renal
morphological findings and the activity and chronicity index were
assessed with the Wilcoxon rank-sum test. Differences in fre-
quency distributions between groups were tested by means of the
Cochran-Mantel-Hainszel test.
Patient and kidney survival curves are presented using Kaplan-
Meier estimates for the survival distribution. The starting date of
the survival curves was the date on which treatment with cyclo-
phosphamide and/or steroids was instituted. If no specific treat-
ment was given after a diagnosis of vasculitis had been made, the
date of the diagnosis was used as the starting date. The endpoints
were the date of initiation of maintenance dialysis and death. If
death occurred within three months after the starting date without
recovery of renal function, the patient was censored for the kidney
survival analysis; three months of treatment was chosen, arbi-
trarily, as the time interval after which no further improvement in
renal function is to be expected. Differences between curves were
tested with the log-rank test. A stepwise procedure based on the
log-rank test was used for testing the influence of the following
parameters on the survival curves: age, sex, type of autoantibody,
baseline serum creatinine, activity index and chronicity index. The
level of significance used was 0.05.
Results
Patients
Between January 1985 and January 1993, sera from 1780
patients were tested for ANCA by indirect immunofluorescence
(hF). Two hundred and twenty patients tested positive for ANCA
by hF. Antigen determination was not performed in 48 patients
and negative in 62 others. The diagnoses in these 110 patients are
shown in Table 1. The majority had diseases unrelated to (sys-
temic) vasculitis. Vasculitis or renal limited disease was present in
15 c-ANCA and in 15 p-ANCA positive patients, and renal
involvement in nine and eight of these patients, respectively. Since
the antigen specificity or specificities were unknown or negative in
these patients they were excluded from further analysis.
Antibodies against PR3 and/or MPO were detected in the
remaining 110 patients. Six patients had antibodies aimed at more
than one target antigen and were excluded (four patients had both
aPR3 and aMPO, one had aPR3 and anti-elastase and another
had aMPO and anti-elastase). Twelve other patients were ex-
cluded because they had been diagnosed with vasculitis and/or
glomerulonephritis before January 1985. The remaining 92 pa-
tients were included in the study: 46 patients had aPR3 and 46
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Wegener's vasculitis
Microscopic polyangiitis
Churg-Strauss syndrome
Henoch-Shönlein
purpura
Temporal arteritis
Cerebral angiitis
Leukocytoclastic vas.
Focal segmental
glomeruloscierosis
Hematuria/proteinuria
ed
Systemic lupus
elythematosus
CREST syndrome
SjOgren's syndrome
Rheumatoid arthritis
Arthritis eci
Polymyalgia Rh.
Sarcoidosis
Inflammatory bowel
disease
Scierosing cholangitis
Recurrent sinusitis/otitis
Interstitial lung disease
Pneumoconiosis
Bronchioalveolar cell
care.
Pneumonia
Bacteremia/sepsis
Idiopathic pericarditis
Cholesterol embolism
Rhabdomyolysis
Miscellaneous
Number between brackets represents the number of patients with renal
involvement.
Interstitial nephritis with granulomata.
b Pneumococcus.
CE. coli (1), Staphyloccus au. (2).d Febris cci, idiopathic cardiomyopathy.
C Chronic fatigue, episcleritis, vitamin C deficiency.
Cat-scratch disease, Hashimoto's thyroiditis, recurrent parotitis, poly-
neuropathy.
patients had aMPO. Seventeen patients with aPR3 and six
patients with aMPO participated in our previous study concerning
ANCA-associated glomerulonephritis [161.
Patients characteristics and organ involvement
The demographic and clinical characteristics are listed in Table
2. The patients with aMPO had a higher median age than the
patients with aPR3. The mean number of involved organs in the
aPR3 group exceeded that of the aMPO group. The prevalence of
renal involvement, however, did not differ between both antibody
groups. When the patients with renal involvement (N = 69) were
analyzed separately, patients with aPR3 (median age 54.5 years;
interquartile range 42 to 62) were still younger than patients with
aMPO (median age 63 years; interquartile range 51 to 74; P <
aPR3 aMPO
Characteristic N = 46 N = 46 P value
Male/female 26/20 25/21 NS
Age years (median; 56 (42—63) 63 (5 1—74) <0.05
(interquartile range))
Number of affected organs 3.9 1.4 2.2 1.1 <0.01
per patient (mean SD)
Organ involvement
Kidney 38 (83%) 31(67%) NS
Upper respiratory tract 40 (87%) 13 (28%) <0.01
Lower respiratory tract 24 (52%) 14 (30%) NS
Eye 18 (39%) 6 (13%) <0.01
Musculoskeletal system 31(67%) 23 (50%) NS
Skin 10 (22%) 9 (20%) NS
Nervous system 12 (26%) 3 (7%) =0.01
Abbreviation used is NS, not significant.
Table 3. Clinical groups according to antibody specificity
All aPR3 aMPO
Characteristic N = 92 N = 46 N = 46
No renal involvement 23 8 15
Renal involvement
Renal-limited disease 20 0 20
Nonpulmonaiy extra-renal disease 20 16 4
Pulmonary-renal disease
Without granuloma 20 13 7
With granuloma 9 9 0
0.01). A marked paucity of extra-renal organ involvement was
again noted in the patients with aMPO (number SD of
extra-renal involved organs in aMPO and aPR3: 1.2 1.2 and 3.3
1.1, respectively; P < 0.01). Similar results were obtained when
the IIF-ANCA positive patients without ELISA results, but with
vasculitis or renal limited disease were included and the analysis
repeated with the immunofluorescence staining pattern as the
discriminator (data not shown).
Table 3 shows the clinical characterization of the patients with
renal involvement (N = 69). Pulmonary-renal disease was found
in 29 patients. Granulomatous inflammation was found in nine of
these patients (29%). These nine patients met the Godman and
Churg criteria for Wegener's granulomatosis [18]. If less restric-
tive criteria would be applied, all other patients in this group had
a form of Wegener's vasculitis or the so-called pulmonary-renal
syndrome [13]. aMPO were found in all of the patients with
renal-limited disease but were less frequently detected than aPR3
in patients with nonpulmonary extra-renal disease and in patients
with pulmonary-renal disease (difference in frequency distribution
between aPR3 and aMPO, P < 0.01).
Pre-treatment course of renal function
This analysis was performed only in the patients with renal
involvement (N = 69). Asymptomatic hematuria with normal
renal function (serum creatinine < 120 mol/liter) was present in
two patients with aMPO. All others had an active urinary sedi-
ment and variable degrees of renal function impairment. The
median baseline serum creatinine was 302 p.mol/liter (interquar-
tile range: 132 to 555) in patients with aPR3- and 428 mol/liter
Table 1. Diagnoses in the 110 ANCA-IIF positive patients that were
not tested (N = 48) or negative (N = 62) for aPR3 and aMPO
Table 2. Demographic characteristics and organ involvement
Not tested
c-ANCA p-ANCA(N=24) (N=24)
5 (3)
5(3) 4(3)
2
1(1)
1
2 1
1
1 1(1C)
6
2
4 2
3
1
1
1(1)
2"
Negative
c-ANCA p-ANCA(N=16) (N=46)
2(1)
4 (2)
1(1)
1(1) 1
1(1)
1 (1)
3
2
3 4
2
6
3 3
3(1") 1
4 (3C)
2
2
3C
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Fig. 1. Doubling of pre-treatment serum creatinine within a certain time
interval prior to the start of treatment in patients with renal involvement (N =
69). The numbers on top of the bars denote the percentage of the total
number of patients with that particular autoantibody. In 4 patients with
aPR3 () and in 4 patients with aMPO () there were not sufficient
pre-treatment serum creatinine values available for analysis.
(interquartile range: 191 to 812) in patients with aMPO-associ-
ated renal disease (NS). The courses of the pre-treatment renal
function loss in both antibody groups are summarized in Figure 1.
Since separate analyses of patients with (N = 36) and without
(N = 33) histological proof of renal involvement yielded identical
results (data not shown), the data for all patients with renal
involvement have been pooled. Overall, patients with aPR3-
showed a faster deterioration of renal function than patients with
aMPO-associated renal disease. The clinical pattern of a renal
crisis was found predominantly in patients with aPR3. Conversely,
a pattern of a doubling of serum creatinine for more than six
months was observed almost exclusively in patients with aMPO. In
line with the above observations, the slope of the reciprocal serum
creatinine values versus time, was steeper in the aPR3 (N = 34)
than in the aMPO group (N = 27): the median slope was —407 X
10 liter!j.tmol!day (interquartile range from —587 X 10—6 to
—277 X 106) in patients with aPR3 and —22.5 X 10—6 liter!
.tmol/day (interquartile range from —79.7 x 10—6 to —3.3 X
106) in patients with aMPO (P < 0.01). The results were
unaffected when the ANCA-IIF positive patients without ELISA
results were included in the analysis. Renal function deteriorated
significantly faster in the c-ANCA positive patients with renal
involvement compared with the p-ANCA positive group (data not
shown).
Histological studies
A renal biopsy was performed in 17 (45%) patients with aPR3-
and in 20 (65%) patients with aMPO-associated renal disease.
One biopsy from a patient with aMPO was inadequate and was
not classified. One patient with aMPO showed a diffuse prolifer-
ative glomerulonephritis. All other biopsies showed evidence of a
crescentic glomerulonephritis. The immunofluorescence studies
were basically negative, except for the patient with the diffuse
proliferative glomerulonephritis mentioned above and one other.
A more detailed description of their biopsy findings is provided in
the paragraph on treatment. Arteritis was found in the renal
biopsies from two patients with aPR3 and from one patient with
Characteristic
aPR3
N = 17
aMPO
N = 19 p value
Glomerular lesionsa
Crescents 61.7 22.8 44.3 29.7 0.076
Necrosis 47.1 31.0 21.4 19.6 0.009
Sclerosis 4.5 8.4 17.0 16.1 0.01
Tubulo-interstitial lesions'
Fibrosis 1.5 0.5 1.7 0.6 0.16
Tubular atrophy
Activity index
Chronicity index
1.2 0.6
10.2 3.8
4.5 2.6
1.5 0.8
7.3 3.2
7.0 3.1
0.21
0.029
0.015
a Percentage of total number of glomeruli
b Semi-quantitatively graded on a scale from 0 to 3
No treatment Corticosteroids Cyclophosphamide
+ corticosteroids
Fig. 2. Treatment modalities in patients with renal involvement (N = 69).
Symbols are: Group 1 (): renal-limited disease; Group 2 (ETI): renal
disease and nonpulmonaiy extra-renal disease; Group 3 (): pulmonary-
renal disease.
aMPO. A granuloma was found in a kidney biopsy from 1 patient
with aPR3. The morphological findings in both antibody groups
are shown in Table 4. Patients with aPR3 had more active and
proliferative lesions than patients with aMPO, whereas biopsies
from the latter group showed more evidence of chronic injury.
These observations are supported by the activity and chronicity
index. Patients with aPR3 had a higher activity index than patients
with aMPO, while the chronicity index showed opposite findings.
Treatment
Figure 2 shows the relation between the treatment and the type
of antibody in the patients with renal involvement (N = 69).
Except for one, all patients (97%) with aPR3-associated renal
disease received both steroids and cyclophosphamide. In contrast,
five patients (16%) with aMPO-associated renal disease were
treated with steroids only and six patients (19%) were not treated
at all (P < 0.01 in comparison with aPR3-group). The latter
patients included three elderly females (75, 67 and 72 years of
age) that presented with hematuria and proteinuria, and an
impaired renal function (serum creatinine 191, 122 and 200
tmol!liter, respectively); one of them suffered transiently from a
purpuric rash. Renal function remained stable or had improved at
last follow-up (112, 122 and 191 .tmol/liter after 20, 12 and 25
months, respectively). The fourth patient was a 17-year-old male
(I)
ci)
cci
0
U)
.0
E
z
25
20
15
10
5
0
Table 4. Morphological findings on renal biopsy
26%
29%
11% 13%
<2 weeks 2 weeks— 3—6
3 months months
aPR340
35
3Q
ci)
250
20
U)
.o 15
E
z
5
0
aMPO aMPO
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0
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Fig. 3. Patient survival in patients with aPR3 (solid line) and aMPO (dashed
line). The figures in parentheses indicate the number of patients that were
available for analysis at that time.
who presented with renal insufficiency (serum creatinine 429
mol/liter) and extensive glomerulosclerosis and interstitial fibro-
sis due to a nephritic process on kidney biopsy. He became dialysis
dependent after a follow-up of 6.5 months. The fifth patient was
a 61-year-old male that developed a proliferative glomerulo-
nephritis in the course of an infectious endocarditis of the mitral
valve due to Legionella pneumophilia. Immunofluorescence stud-
ies showed scattered mesangial deposits of C3 and 1gM along the
glomerular capillary loops, compatible with a post-infectious
glomerulonephritis. His renal function improved after mitral valve
replacement and appropriate antibiotic therapy (serum creatinine
275 j.mol/liter at presentation and 170 molIliter after 43 days
of follow-up). The last patient was a 22-year-old male that
presented with acute renal insufficiency (serum creatinine 2040
jmol/liter) in association with Staphylococcus aureus sepsis after
osteosynthesis for a traumatic crural fracture. A renal biopsy
disclosed a crescentic glomerulonephritis. Immunofluorescence
studies showed scattered deposits of IgG (1+), 1gM (1+) and C3
(3+) along intact glomerular capillary loops. A diagnosis of
post-infectious glomerulonephritis was made. He was treated with
flucloxacilline and hemodialysis for three weeks. His serum cre-
atinine is 180 .tmol/liter at seven months follow-up, although
there is persistent microscopic hematuria.
Survival
The survival curves assessing the probability of death or end-
stage kidney disease are shown in Figures 3 and 4, respectively.
Patient survival did not vary between both antibody groups (P =
0.28) and was at two years 86% in patients with aPR3 and 78% in
patients with aMPO. The kidney survival did not differ between
both antibody groups (P = 0.21) and was at two years 73% in
patients with aPR3- and 61% in patients with aMPO-associated
renal disease. When kidney survival was analyzed separately in
those patients with renal involvement that had been treated with
cyclophosphamide and/or steroids, the two-year kidney survival
again did not vary between the aPR3- and the aMPO-group (P =
0.10; survival at 2 years 73% and 56%, respectively). Separate
analyses of patients with and without histological proof of renal
involvement did not disclose survival differences between both
antibody groups either (data not shown). The results were also not
100 (38)
80 (it,(22) (19) (14)
60
(?)
__LL (11) (9)
(13) (6) (4)
a)o 40
a)
a-
20
0
0 6 12 18 24 30
Time, months
Fig. 4. Kidney survival in patients with aPR3- (solid line) and aMPO-(dashed line) associated renal disease. The dotted line indicates those
patients with aMPO that were treated with cyclophosphamide and/or
steroids. The figures in parentheses indicate the number of patients that
were available for analysis at that time.
affected, when the ANCA-IIF positive patients without ELISA
results but with evidence of vasculitis or renal-limited disease
were included in the analysis.
Therapy-related death occurred in three patients with aPR3
and in four patients with aMPO.
Variables related to outcome
Both age and baseline serum creatinine significantly influenced
patient survival. The levels of both variables were inversely related
with the probability of patient survival.
The baseline serum creatinine value was the only variable that
significantly influenced kidney survival (this was assessed only in
the patients with renal involvement). The baseline serum creati-
nine level was inversely related with the probability of kidney
survival. When patients with aPR3 and aMPO were separately
analyzed, a significant influence of the baseline serum creatinine
level on kidney survival was found in the aMPO-group but not in
the aPR3-group.
Discussion
Since its first description in 1982 [191, a host of articles on the
value of ANCA has appeared, soon followed by studies on the
diagnostic value of antibodies directed against the two major
ANCA targets: proteinase 3 and myeloperoxidase. However,
studies that have specifically compared the clinical features, the
renal morphology and the outcome between patients with aPR3-
and aMPO-associated renal disease are relatively scarce [1, 14,
15]. As far as we know, the pre-treatment courses of renal
function in patients with aPR3 and aMPO have not yet been
compared. In some studies, patient selection criteria included the
presence of renal involvement and a renal biopsy [1, 14]. Since
patients with a more indolent loss of renal function are less likely
to be biopsied, such a selection may lead to bias. Therefore, we
selected our patients from general hospitals without the restric-
tion of the presence of a specific organ manifestation or renal
biopsy.
The disease spectrum showed a great divergence between
patients with aPR3 and aMPO. Renal-limited disease occurred
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exclusively in patients with aMPO, whereas pulmonary-renal
disease was more frequent in patients with aPR3. Granuloma
formation was seen only in patients with aPR3. These observa-
tions are in accordance with earlier publications [9, 13, 14, 20] and
underscore the importance of the determination of the target
antigen in evaluating a patient with ANCA-associated vasculitis.
The prevalence of renal involvement did not vary in patients with
either autoantibody. Although the kidney is a major target organ
in vasculitides associated with both autoantibodies, our results
confirm previous studies [7, 9, 151 that showed that one out of
every five patients lacks renal involvement.
A remarkable finding is the difference in the rate of the loss of
renal function before treatment was instituted between patients
with aPR3 and aMPO. In as many as 60% of patients with
aPR3-associated renal disease, serum creatinine doubled within
two weeks prior to treatment. In contrast, most patients with
aMPO showed a doubling of serum creatinine over more than
three months. Some of these patients with aMPO fit into a pattern
of a 'not so rapidly progressive' form of glomerulonephritis
progressing to uremia over the years as described by several
authors [16, 21, 221. The observed difference in the rate of renal
function loss is the more noteworthy because the renal patholog-
ical diagnosis was identical in both groups: a pauci-immune
crescentic glomerulonephritis. However, upon detailed histologi-
cal examination, patients with aPR3-associated renal disease were
found to have more active lesions, whereas patients with aMPO-
associated renal disease had more chronic lesions. This observa-
tion corresponds well with the difference in the rate of renal
function loss: more active lesions in the group with the faster
decline and more chronic ones in the group with the slower
decline in renal function. Our observations differ from those
reported by Jennette, Wilkman and Falk [141. These authors
found no differences between the renal biopsies of patients with
c-ANCA and p-ANCA (the majority representing aPR3 and
aMPO, respectively). However, they mainly used active parame-
ters in their comparison, such as the percentage of glomeruli with
crescents and necrosis and the presence of renal arteritis. In
addition, we used parameters relating to chronic damage like the
percentage of glomeruli with sclerosis and the severity of intersti-
tial fibrosis and atrophy. We also used a renal pathology scoring
system [16], adapted from the one in use for scoring kidney
biopsies from patients with systemic lupus etythematosus [23]. As
we stated above, apart from the different parameters used for
scoring, a different patient selection is likely to have contributed
to the different results.
In line with earlier observations, we found a comparable
two-year kidney survival in both antibody groups [1]. Since renal
function deteriorated faster in the patients with aPR3, one would
have expected a less favorable kidney survival in this group. The
fact that we observed no difference in outcome requires some
explanation. A reasonable assumption would be that patients with
a fulminant renal function loss and extensive organ involvement
(predominantly aPR3) are recognized, and therefore biopsied, at
an earlier stage than are patients with a slower rate of renal
function loss and fewer organs involved (predominantly aMPO).
We hypothesize that the fulminant loss of renal function is caused
by acute renal damage over a short period of time. In these
patients (predominantly aPR3), crescents are formed but are not
yet transformed to fibrous tissue at the time of renal biopsy. The
acute pathological lesions are largely reversible upon early and
adequate treatment [24—26]. In contrast, a more protracted
course of renal function loss (predominantly aMPO) probably
goes together with a more prolonged and/or repetitive renal
damage in time. These patients also have less extended extra-
renal organ involvement. Therefore, a final diagnosis will be
reached relatively late in these patients and at a stage that renal
scaring is more likely to have occurred. Thus a biopsy is likely to
show predominantly chronic lesions. Therefore, the influence on
kidney survival of the more acute and extensive—but potentially
reversible—disease in the one group may be roughly the same as
the effect of the more indolent—but irreversible—damage in the
other group. Earlier recognition of aMPO-associated renal dis-
ease and consequent earlier treatment, at a stage when renal
lesions are reversible, could possibly favorably affect renal out-
come.
The high number of deaths related to immunosuppressive
therapy points to the necessity of careful assessment of the
benefits of this potentially perilous treatment [27—29]. Proper
evaluation of the renal biopsy appears to be valuable in this
process. In a previous study, biopsies with a high chronicity and a
low activity index predicted a high renal fatality outcome despite
vigorous immunosuppressive therapy [16]. In this study mainly
patients with aMPO-associated glomerulonephritis fit this de-
scription. Age and presenting serum creatinine appeared to be a
significant predictor of kidney survival in the study of Hogan et al
[30]. Although it is difficult to give cut-off values for age, pretreat-
ment renal function loss and renal biopsy findings to decide
whether or not to treat a patient, several inferences can be derived
from our study and the others cited above. It seems reasonable to
withhold immunosuppressive treatment in patients with MPO-
associated renal-limited disease and one of the following features:
age older than 70 years, an indolent renal function loss (doubling
of serum creatinine in more than 3 months) and/or a high
chronicity index on renal biopsy. In these instances, a short course
of steroids may still be considered. At the same time, involvement
of other organs, for example, pulmonary involvement or scleritis,
may still necessitate aggressive immunosuppressive therapy even
when such a therapy is not warranted anymore for renal function
preservation.
This study gives no answer to the question why ANCA of
different specificities are associated with a different distribution
and extent of vasculitis. If we assume that ANCA have a patho-
genetic role [11], the site and extent of the resulting vascular
injury may be influenced by different physicochemical properties
of these autoantibodies.
We may conclude that, although the pathological diagnosis of a
pauci-immune crescentic glomerulonephritis is essentially the
same in patients with either antibody, most patients with aPR3
develop renal failure within weeks, whereas most patients with
aMPO have a slower decline of renal function. This is associated
with more active lesions in the renal biopsies from patients with
aPR3 and more chronic lesions in the renal biopsies from patients
with aMPO. We suggest that the presenting serum creatinine, the
patient age and a proper evaluation of a renal biopsy should be
used in deciding whether potentially dangerous immunosuppres-
sive treatment is appropriate in patients with aMPO-associated
renal-limited disease.
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